Skip to Content

UPMC Physicians and Researchers Present at the Society for Immunotherapy of Cancer 2019 Annual Meeting

October 28, 2019

UPMC Hillman Cancer Center and UPMC Immune Transplant and Therapy Center physicians and researchers will be well-represented at the Society for Immunotherapy of Cancer (SITC) 2019 Annual Meeting from November 6 – 10 in National Harbor, Md. 

The event brings together stakeholders across the cancer immunotherapy field to advance the science, discover breakthroughs and educate the world to improve outcomes for all cancer patients. 

Following is a list of awards, courses, posters, and presentations to be delivered by physicians and researchers from UPMC.


Olivera Finn, PhD, received the 2019 Richard V. Smalley, MD, Memorial Award and Lectureship, the most prestigious award bestowed by SITC. The award honors those that have been pioneers in their work and have made a notable impact worthy of high regard by their peers. As part of her award, Dr. Finn will serve as a primary keynote presenter. 


Thursday, Nov. 7

Primer on Tumor Immunology and Cancer ImmunotherapyTM 
Primer Session 2: Tumor Immunity II, 10:10 a.m. – noon 
Regulation of Cancer Immunity by Metabolic and Microbiome Interactions
Greg Delgoffe, PhD

Meet the Expert Lunch, noon – 1 p.m. 
Table 6: Gaining a Network and Leveraging Support
Tullia Bruno, PhD

Workshop Session 5: Systemic Combinations, 2 – 4:55 p.m.
Jason Luke, MD, FACP

Primer on Tumor Immunology and Cancer ImmunotherapyTM 
Primer Session 4: Current IO Immunotherapy, 3:10 – 4:55 p.m.
Combination Immunotherapies
Leisha Emens, MD, PhD

Friday, Nov. 8

Richard V. Smalley, MD Memorial Lectureship, 8:35 – 9:25 a.m.
Traveling the Cancer Vaccine Road and Reaching My Destination
Keynote Speaker: Olivera J. Finn, PhD

Session 203: Late-Breaking Abstract Session, 12:15 p.m.
Durable responses in anti-PD-1 refractory melanoma following intratumoral injection of  Toll-like receptor 9 (TLR9) agonist CMP-001, in combination with pembrolizumab
John Kirkwood, MD

Concurrent Rapid Oral Abstract Presentations – Basic Research (with Q&A), 12:45 – 1:45 p.m.
(O50) PD1+ T regulatory cells in metastatic cancer patients co-express CD39 and exhibit attenuated suppressive function due to decreased survival
Richard Wu, MD, PhD

Session 204: Immune Checkpoints: Newer Targets and Update on Combinations, 2:00 – 4:20 p.m.
Novel Targets: TIM-3
Presenter: Hassane M. Zarour, MD
(O40) Immunobiology and clinical activity of CPI-006, an anti-CD73 antibody with immunomodulating properties in a phase 1/1b trial in advanced cancers
Jason Luke, MD, FACP

Concurrent Session 206: High Impact Clinical Trials
(O29) Phase I study of multisite stereotactic body radiotherapy plus nivolumab and urelumab or nivolumab and cabiralizumab in patients with advanced solid tumors
Second Author: Jason Luke, MD, FACP

Concurrent Session 209: Virus Driven Cancers, 4:50 – 6:15 p.m.
HPV and Head and Neck Cancers
Presenter and Session Co-chair: Robert Ferris, MD, PhD

Concurrent Session 205: Biology of T cells, 4:50 – 6:15 p.m.
(O49) Chronic activation under hypoxia drives T cell differentiation to exhaustion
Nicole E. Scharping, PhD 

Concurrent Session 208: Tumor Cell Atlas Efforts – Big Data (with Q&A), 4:50 – 6:15 p.m.
(O42) Transcriptional dissection reveals antitumor role of T follicular helper cells in head and neck cancer
Anthony R. Cillo, PhD

Saturday, Nov. 9

Poster Session
P296: BMI, irAE and gene expression signatures predict resistance and survival to immune-checkpoint inhibition in renal cell carcinoma
Riyue Bao, PhD; Jason J. Luke, MD, FACP

Concurrent Rapid Oral Abstract Presentations – Basic (with Q&A) 12:50 – 1:50 p.m.
(O69) Helicobacter hepaticus remodels the tumor immune microenvironment and reduces colorectal tumor burden
Abigail E. Overacre-Delgoffe, PhD 

Session 306: Presidential Session, 2:05 – 3:30 p.m.
Expert Discussant: Dario A.A. Vignali, PhD

Concurrent Session 313: Immunotherapy Advances in Skin Cancer, 5:15 – 6:30 p.m.
(O34) Phase II Trial of Neoadjuvant Nivolumab (Nivo) and Intra-Tumoral (IT) CMP-001 in High Risk Resectable Melanoma (MEL): Preliminary Results
Diwakar Davar, MD 

Annual Cocktail Reception

Additionally, Leisha Emens, MD, PhD, Jason Luke, MD, FACP, Dario A. Vignali, PhD, and Hassane Zarour, MD will host a cocktail reception to honor Olivera J. Finn, PhD, 2019 recipient of the Richard V. Smalley, MD, Award on Friday, Nov. 8 from 5:30 to 7:30 p.m. at The Westin Washington National Harbor. For more information and to RSVP for the event, please click here.